Drug Trial Radar · NCT07913074
A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Oct 23, 2026
Primary completion
Jun 30, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Tavo BiotherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- True North Therapeutics
- First posted
- Nov 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is evaluating a new eye drop containing pregabalin (TB0001) as a potential treatment for people with primary open-angle glaucoma or ocular hypertension. The study aims to determine whether TB0001 lowers eye pressure as effectively as timolol, a commonly used glaucoma eye drop, while remaining safe and well tolerated. Participants will be randomly assigned to receive one of three strengths of TB0001 or timolol for 28 days. Eye pressure, eye health, side effects and tolerability will be assessed throughout the study. The results will help identify the most appropriate dose of TB0001 for future clinical studies.
Conditions
- Primary Open - Angle Glaucoma (POAG)
- Ocular Hypertension (OHT)
Interventions
Arm 1: TB0001 ophthalmic solution 0.9%Drug
TB0001 is a sterile, clear colorless to slightly yellow pregabalin ophthalmic solution at concentrations of 0.9%
Arm 2: TB0001 ophthalmic solution 1.2%Drug
Pregabalin ophthalmic solution (TB0001) 1.2% is a sterile, colorless to slightly yellow solution.
TB0001 ophthalmic solution 1.5%Drug
TB0001 is a sterile, clear, colorless to slightly yellow solution
Timolol 0.05% eye dropsDrug
Timolol ophthalmic solution 0.5% will be administered twice daily (AM + PM)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from mean diurnal baseline IOP to mean diurnal IOP at Day 28Time frame: Baseline (pre-treatment) and Day 28 (approximately 1, 3 and 6 hours after the morning study treatment administration; primary timepoint). Baseline mean diurnal intraocular pressure is calculated from measurements obtained prior to treatment initiation.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Global Research Management, Inc
Glendale, California · Recruiting
Eye Research Foundation, Inc
Newport Beach, California · Recruiting
Piedmont Eye Center
Lynchburg, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.